SENATE BILL 961
J5, J4 5lr3305
By: Senator Mautz
Introduced and read first time: January 28, 2025
Assigned to: Finance
A BILL ENTITLED
1 AN ACT concerning
2 Maryland Medical Assistance Program and Health Insurance –
3 Pharmacogenomic Testing – Required Coverage
4 FOR the purpose of requiring the Maryland Medical Assistance Program and certain health
5 insurers, nonprofit health services plans, and health maintenance organizations to
6 provide coverage for single–gene and multigene pharmacogenomic testing in certain
7 circumstances; limiting the prior authorization requirements that certain health
8 insurers, nonprofit health services plans, and health maintenance organizations may
9 implement for pharmacogenomic testing; and generally relating to coverage of
10 pharmacogenomic testing.
11 BY adding to
12 Article – Health – General
13 Section 15–102.3(m) and 15–103(a)(2)(xxv)
14 Annotated Code of Maryland
15 (2023 Replacement Volume and 2024 Supplement)
16 BY repealing and reenacting, without amendments,
17 Article – Health – General
18 Section 15–103(a)(1)
19 Annotated Code of Maryland
20 (2023 Replacement Volume and 2024 Supplement)
21 BY repealing and reenacting, with amendments,
22 Article – Health – General
23 Section 15–103(a)(2)(xxiii) and (xxiv)
24 Annotated Code of Maryland
25 (2023 Replacement Volume and 2024 Supplement)
26 BY adding to
27 Article – Insurance
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from exist in g l aw . *sb0961*

2 SENATE BILL 961
1 Section 15–861
2 Annotated Code of Maryland
3 (2017 Replacement Volume and 2024 Supplement)
4 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
5 That the Laws of Maryland read as follows:
6 Article – Health – General
7 15–102.3.
8 (M) (1) BEGINNING JULY 1, 2026, THE PROVISIONS OF § 15–861(C) AND
9 (D) OF THE INSURANCE ARTICLE APPLY TO MANAGED CARE ORGANIZATIONS IN THE
10 SAME MANNER THEY APPLY TO CARRIERS.
11 (2) A MANAGED CARE ORGANIZATION THAT DOES NOT COMPLY WITH
12 § 15–861(C) AND (D) OF THE INSURANCE ARTICLE SHALL BE SUBJECT TO A
13 MONETARY PENALTY OF UP TO $10,000 PER INSTANCE OF NONCOMPLIANCE AND AN
14 ADDITIONAL PENALTY OF $1,000 PER DAY FOR EACH DAY THE NONCOMPLIANCE
15 CONTINUES AFTER NOTIFICATION OF NONCOMPLIANCE FROM THE DEPARTMENT
16 TO THE MANAGED CARE ORGANIZATION.
17 (3) (I) THE DEPARTMENT MAY REQUIRE A MANAGED CARE
18 ORGANIZATION THAT DOES NOT COMPLY WITH § 15–861(C) AND (D) OF THE
19 INSURANCE ARTICLE TO SUBMIT AND IMPLEMENT A CORRECTIVE ACTION PLAN
20 WITHIN 30 DAYS AFTER RECEIPT OF A REQUEST FOR A CORRECTIVE ACTION PLAN
21 FROM THE DEPARTMENT.
22 (II) FAILURE TO IMPLEMENT A CORRECTIVE ACTION PLAN
23 REQUIRED UNDER SUBPARAGRAPH (I) OF THIS PARAGRAPH MAY RESULT IN
24 ADDITIONAL ENFORCEMENT ACTIONS.
25 (4) A MANAGED CARE ORGANIZATION SUBJECT TO A PENALTY UNDER
26 THIS SUBSECTION MAY REQUEST AN ADMINISTRATIVE HEARING UNDER TITLE 10,
27 SUBTITLE 2 OF THE STATE GOVERNMENT ARTICLE.
28 (5) (I) THE DEPARTMENT SHALL CONDUCT PERIODIC AUDITS AND
29 REVIEWS OF MANAGED CARE ORGANIZATIONS TO DETERMINE COMPLIANCE WITH
30 THIS SUBSECTION.
31 (II) THE DEPARTMENT SHALL ESTABLISH A PROCESS FOR
32 PATIENTS, PRESCRIBERS, AND LABORATORIES TO REPORT INSTANCES OF
33 NONCOMPLIANCE WITH THIS SUBSECTION.

SENATE BILL 961 3
1 15–103.
2 (a) (1) The Secretary shall administer the Maryland Medical Assistance
3 Program.
4 (2) The Program:
5 (xxiii) Beginning on July 1, 2025, shall provide, subject to the
6 limitations of the State budget, and as permitted by federal law, coverage for biomarker
7 testing in accordance with § 15–859 of the Insurance Article; [and]
8 (xxiv) Beginning on January 1, 2025, shall provide coverage for
9 prostheses in accordance with § 15–844 of the Insurance Article; AND
10 (XXV) BEGINNING ON JULY 1, 2026, SHALL PROVIDE COVERAGE
11 FOR SINGLE–GENE AND MULTIGENE PHARMACOGENOMIC TESTING IN ACCORDANCE
12 WITH § 15–861 OF THE INSURANCE ARTICLE.
13 Article – Insurance
14 15–861.
15 (A) IN THIS SECTION, “PHARMACOGENOMIC TESTING” MEANS LABORATORY
16 GENETIC TESTING, INCLUDING SINGLE–GENE AND MULTIGENE PANEL TESTING,
17 CONDUCTED TO EVALUATE HOW AN INDIVIDUAL’S GENETIC PROFILE MAY IMPACT
18 THE EFFICACY, SAFETY, OR TOXICITY OF MEDICATIONS.
19 (B) THIS SECTION APPLIES TO:
20 (1) INSURERS AND NONPROFIT HEALTH SERVICE PLANS THAT
21 PROVIDE HOSPITAL, MEDICAL, OR SURGICAL BENEFITS TO INDIVIDUALS OR GROUPS
22 ON AN EXPENSE–INCURRED BASIS UNDER HEALTH INSURANCE POLICIES OR
23 CONTRACTS THAT ARE ISSUED OR DELIVERED IN THE STATE; AND
24 (2) HEALTH MAINTENANCE ORGANIZATIONS THAT PROVIDE
25 HOSPITAL, MEDICAL, OR SURGICAL BENEFITS TO INDIVIDUALS OR GROUPS UNDER
26 CONTRACTS THAT ARE ISSUED OR DELIVERED IN THE STATE.
27 (C) AN ENTITY SUBJECT TO THIS SECTION SHALL PROVIDE COVERAGE FOR
28 SINGLE–GENE AND MULTIGENE PHARMACOGENOMIC TESTING IF:
29 (1) THE PHARMACOGENOMIC TESTING IS ORDERED BY A TREATING
30 PROVIDER FOR AN INSURED OR ENROLLEE WITH A DIAGNOSIS OF DEPRESSION OR
31 ANXIETY; AND

4 SENATE BILL 961
1 (2) THE TREATING PROVIDER IS CONSIDERING A MEDICATION
2 CHANGE, DOSE ADJUSTMENT, OR AUGMENTATION AND THE MEDICATION UNDER
3 CONSIDERATION HAS A KNOWN GENE–DRUG INTERACTION.
4 (D) A PRIOR AUTHORIZATION REQUIREMENT IMPOSED FOR COVERAGE
5 REQUIRED UNDER THIS SECTION:
6 (1) SHALL PROVIDE A CLEAR AND MEANINGFUL PATHWAY FOR
7 COVERAGE THAT ENSURES TIMELY ACCESS TO THE COVERAGE REQUIRED UNDER
8 SUBSECTION (C) OF THIS SECTION;
9 (2) SHALL REQUIRE ONLY THE MINIMUM NECESSARY
10 DOCUMENTATION FROM THE TREATING PROVIDER TO DETERMINE WHETHER THE
11 PATIENT MEETS THE CRITERIA FOR COVERAGE UNDER SUBSECTION (C) OF THIS
12 SECTION;
13 (3) SHALL ALLOW A SUFFICIENT AUTHORIZATION TIME FRAME
14 FOLLOWING THE COLLECTION OF A SPECIMEN FOR PHARMACOGENOMIC TESTING
15 FOR THE SUBMISSION OF A PRIOR AUTHORIZATION REQUEST AND CLAIMS RELATED
16 TO PHARMACOGENOMIC TESTING;
17 (4) SHALL ALLOW A PRIOR AUTHORIZATION REQUEST TO BE
18 SUBMITTED BY A TREATING PROVIDER OR A LABORATORY PROVIDER; AND
19 (5) MAY NOT IMPOSE UNDUE ADMINISTRATIVE BURDENS OR DELAYS
20 THAT CREATE BARRIERS TO CARE FOR AN INSURED OR ENROLLEE.
21 (E) (1) AN ENTITY THAT DOES NOT COMPLY WITH THIS SECTION SHALL
22 BE SUBJECT TO A MONETARY PENALTY OF UP TO $10,000 PER INSTANCE OF
23 NONCOMPLIANCE AND AN ADDITIONAL PENALTY OF $1,000 PER DAY FOR EACH DAY
24 THE NONCOMPLIANCE CONTINUES AFTER NOTIFICATION OF NONCOMPLIANCE
25 FROM THE COMMISSIONER TO THE ENTITY.
26 (2) (I) THE COMMISSIONER MAY REQUIRE AN ENTITY THAT DOES
27 NOT COMPLY WITH THIS SECTION TO SUBMIT AND IMPLEMENT A CORRECTIVE
28 ACTION PLAN WITHIN 30 DAYS AFTER RECEIPT OF A REQUEST FOR A CORRECTIVE
29 ACTION PLAN FROM THE COMMISSIONER.
30 (II) FAILURE TO IMPLEMENT A CORRECTIVE ACTION PLAN
31 REQUIRED UNDER SUBPARAGRAPH (I) OF THIS PARAGRAPH MAY RESULT IN
32 ADDITIONAL ENFORCEMENT ACTIONS.

SENATE BILL 961 5
1 (3) AN ENTITY SUBJECT TO A PENALTY UNDER THIS SUBSECTION MAY
2 REQUEST AN ADMINISTRATIVE HEARING UNDER TITLE 10, SUBTITLE 2 OF THE
3 STATE GOVERNMENT ARTICLE.
4 (F) (1) THE COMMISSIONER SHALL CONDUCT PERIODIC AUDITS AND
5 REVIEWS OF ENTITIES SUBJECT TO THIS SECTION TO DETERMINE COMPLIANCE
6 WITH THIS SECTION.
7 (2) THE COMMISSIONER SHALL ESTABLISH A PROCESS FOR
8 PATIENTS, PRESCRIBERS, AND LABORATORIES TO REPORT INSTANCES OF
9 NONCOMPLIANCE WITH THIS SECTION.
10 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
11 October 1, 2025.

[DELETED: :CA      5     A M P F i p c l t p a r t c h i i f p t a g r t c o p B  A S  A  ( B  A S  A  ( B  A S  A  ( B  A]
[DELETED:  S  S  A  (  S T A 1 ) ( BJ1,2,§1(E U     C )I  N RS ( 1()()IC A D O T N R S B S T A     E ( () TH E M R A M C T D N C W  C A D O T1()( R T S A I A C A P   ET.  () IA T I A C A P U S I O T P M R IS (  I 12SGA.   T O RE ( () TH EN  () TIH E S E A P FS PS A L T R I ON]
[DELETED: S 3 1  ( ( T S s a t M M A P   ( T    ( o J 1 2 s p s t t l t ad    ( o J 1 2 s p c f p  ()BJ1,2VE U   EG    N R11I . A() I,“NN PG  TG I SEG A M P TG–LSY Y S,.() T:H ( A N H S P TL L  A EEI B U H I P O TE ; ( M O T PL L  T.() NEG: (Y ]
[DELETED:  S  ( T P I C A ME D AT O A A T M UEDN.()  P A R I F C ( P A C A M P F C ); ( R O T M N C F U C ON ( A A S A T FG ( A A P A R T BR  (() ( N S T A M P O U T  P I O   N C A N O N O. ( () TH O C W T S T S A I A C   OR.  () IA T I A C A P U S I O T P M R IS]
[DELETED: S 5 (  A A H U I  U  O T1,SGA. O RE() ( TH O S C P A A O E S T T S T D CN ( T O S E A P FS PS A L T R I ON  S A B I F E T t A s t e O]